ADC Therapeutics SA (NYSE: ADCT), a pioneer in antibody drug conjugates (ADCs) with a current market capitalization of $131 million, has reported promising results from the LOTIS-7 Phase 1b clinical trial. The trial evaluated the combination of ZYNLONTA and glofitamab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). An overall response rate (ORR) of 95.5% and a complete response (CR) rate of 90.9% were observed among 22 evaluable patients.
The data, as of January 17, 2025, indicated that the median duration of response (DOR) was not reached. The safety profile was described as manageable, with neutropenia being the most common Grade ≥3 treatment-emergent adverse event. Other Grade 3/4 adverse events included generalized edema, pericardial effusion, and pneumonia, each reported in 3.2% of patients.
The results will be presented at the European Hematology Association 2025 Congress (EHA2025) on Saturday, June 14, and at an oral encore presentation at the International Conference on Malignant Lymphoma (ICML) on Friday, June 20.
The LOTIS-7 study includes a multi-arm design to evaluate ZYNLONTA in combination with different agents for B-cell non-Hodgkin lymphoma (B-NHL). The primary endpoints of the study are safety and tolerability, with secondary efficacy endpoints including ORR, DOR, CRR, PFS, RFS, and OS.
ZYNLONTA, a CD19-directed ADC, has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Its mechanism involves binding to CD19-expressing cells, internalization, and the release of a potent payload leading to tumor cell death.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.